e8vk
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
Current Report Filed Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report
(Date of earliest event reported): January 7, 2008
Repros Therapeutics Inc.
(Exact name of registrant as specified in its charter)
| |
|
|
|
|
| Delaware
|
|
001-15281
|
|
76-0233274 |
| (State or other jurisdiction of
|
|
(Commission File Number)
|
|
(I.R.S. Employer Identification No.) |
| incorporation or organization) |
|
|
|
|
2408 Timberloch Place, Suite B-7
The Woodlands, Texas 77380
(Address of principal executive offices and zip code)
(281) 719-3400
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy
the filing obligation of the registrant under any of the following provisions (see General
Instruction A.2 below):
|
|
|
| o |
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
|
| o |
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
|
| o |
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
|
| o |
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
|
|
|
| Item 7.01. |
|
Regulation FD Disclosure |
The information in this Current Report is being furnished pursuant to Item 7.01 of Form 8-K
and, according to general instruction B.2. thereunder, the information in this Current Report shall
not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934 or
otherwise subject to the liabilities of that Section. The information in this Current Report shall
not be incorporated by reference into any registration statement pursuant to the Securities Act of
1933.
Repros Therapeutics Inc. (the “Company”) announced today that its President and CEO, Joseph
Podolski, will present a corporate overview on Thursday, January 10, 2008, at 12:00 noon Pacific
Time during the JP Morgan 26th Annual Healthcare Conference at the Westin St. Francis
Hotel in San Francisco, California.
A copy of the Company’s press release is attached hereto as Exhibit 99.1. The press release
is incorporated by reference herein and the foregoing description of the press release is qualified
in its entirety by reference to the attached exhibit.
|
|
|
| Item 9.01. |
|
Financial Statements and Exhibits |
c. Exhibits
| |
|
|
|
|
| Exhibit |
|
|
| Number |
|
Description |
| |
|
|
|
|
| |
99.1 |
|
|
Press Release dated January 7, 2008. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly
caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| |
|
|
|
|
| |
Repros Therapeutics Inc.
|
|
| Date: January 8, 2008 |
By: |
/s/ Louis Ploth, Jr.
|
|
| |
|
Louis Ploth, Jr. |
|
| |
|
Vice President, Business Development and
Chief Financial Officer |
|
| |
EXHIBIT INDEX
| |
|
|
|
|
| Exhibit |
|
|
| Number |
|
Description |
| |
|
|
|
|
| |
99.1 |
|
|
Press Release dated January 7, 2008 |